Covered recipient · General Payments record
RONALD M PUCILLO
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$1,887.94
118 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,874.05 | 117 |
| Education | $13.89 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $371.47 | 33 |
| Novo Nordisk Inc | $256.07 | 18 |
| Stryker Corporation | $172.00 | 1 |
| Lilly USA, LLC | $170.18 | 9 |
| Bayer HealthCare Pharmaceuticals Inc. | $141.28 | 9 |
| Amgen Inc. | $139.22 | 9 |
| ABBVIE INC. | $96.45 | 5 |
| Amarin Pharma Inc. | $72.34 | 4 |
| Horizon Therapeutics plc | $54.85 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $45.06 | 3 |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.71 | 3 |
| Corium, LLC | $42.02 | 2 |
| Merck Sharp & Dohme LLC | $37.93 | 3 |
| GlaxoSmithKline, LLC. | $37.64 | 2 |
| Janssen Pharmaceuticals, Inc | $30.46 | 2 |
| Novartis Pharmaceuticals Corporation | $25.95 | 2 |
| JAZZ PHARMACEUTICALS INC. | $21.63 | 1 |
| SANOFI-AVENTIS U.S. LLC | $20.48 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.94 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $18.66 | 1 |
| Antares Pharma, Inc. | $16.41 | 1 |
| Esperion Therapeutics, Inc. | $15.21 | 1 |
| Arbor Pharmaceuticals, Inc. | $14.05 | 1 |
| Supernus Pharmaceuticals, Inc. | $14.01 | 1 |
| PFIZER INC. | $12.92 | 1 |
Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RONALD M PUCILLO
NPI 1548263106 · CMS profile ID 160158
Allopathic & Osteopathic Physicians / Family Medicine
SUGAR LAND, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1548263106?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RONALD M PUCILLO, NPI 1548263106, CMS profile ID 160158. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1548263106?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). RONALD M PUCILLO, NPI 1548263106, CMS profile ID 160158. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1548263106?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- RONALD M PUCILLO, NPI 1548263106, CMS profile ID 160158, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–118 of 118 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1548263106?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
118 matching records · $1,887.94 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–118 of 118.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $19.22 | 03/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 914228445 | CMS |
| Novartis Pharmaceuticals Corporation | $13.61 | 03/15/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 894248713 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $20.02 | 03/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 929951701 | CMS |
| Horizon Therapeutics plc | $15.10 | 03/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 937676947 | CMS |
| Merck Sharp & Dohme LLC | $11.41 | 03/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944651761 | CMS |
| Novo Nordisk Inc | $22.55 | 03/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899051493 | CMS |
| Novo Nordisk Inc | $14.91 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899466471 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.94 | 02/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 955784863 | CMS |
| Janssen Pharmaceuticals, Inc | $16.57 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886951607 | CMS |
| Amarin Pharma Inc. | $13.06 | 02/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 913921259 | CMS |
| Corium, LLC | $21.56 | 02/07/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 924838173 | CMS |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.83 | 02/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 923704563 | CMS |
| Esperion Therapeutics, Inc. | $15.21 | 01/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947277689 | CMS |
| Novo Nordisk Inc | $20.26 | 01/18/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 899148437 | CMS |
| ABBVIE INC. | $18.04 | 01/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 891394477 | CMS |
| Amgen Inc. | $22.25 | 01/11/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939847543 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $23.95 | 01/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930254149 | CMS |
| JAZZ PHARMACEUTICALS INC. | $21.63 | 01/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 951334013 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $698,468.50 | 49 |
| PY2024 | Principal investigator | $1,842,674.31 | 63 |
| PY2023 | Principal investigator | $1,086,986.91 | 926 |
| PY2022 | Principal investigator | $1,049,470.14 | 1,455 |
| PY2021 | Principal investigator | $371,869.55 | 12 |
| PY2020 | Principal investigator | $81,954.83 | 8 |
| PY2019 | Principal investigator | $5,265.15 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
49 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $1,329.63 | 12/19/2025 | Non-covered Recipient Entity Javara Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228736783 |
| Principal investigator 1 | PFIZER INC. | $3,815.10 | 11/29/2025 | Non-covered Recipient Entity Javara Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228728597 |
| Principal investigator 1 | PFIZER INC. | $3,815.10 | 11/04/2025 | Non-covered Recipient Entity Javara Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228737363 |
| Principal investigator 1 | PFIZER INC. | $2,543.40 | 10/15/2025 | Non-covered Recipient Entity Javara Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228729937 |
| Principal investigator 1 | ModernaTX, Inc. | $118.56 | 08/28/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002515 |
| Principal investigator 1 | ModernaTX, Inc. | $1,547.00 | 07/28/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011458 |
| Principal investigator 1 | ModernaTX, Inc. | $116.55 | 07/28/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011460 |
| Principal investigator 1 | ModernaTX, Inc. | $2,000.00 | 07/23/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011448 |
| Principal investigator 1 | PFIZER INC. | $5,230.00 | 07/11/2025 | Non-covered Recipient Entity Javara Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228772027 |
| Principal investigator 1 | ModernaTX, Inc. | $3,024.52 | 06/18/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002501 |
| Principal investigator 1 | ModernaTX, Inc. | $51,429.76 | 06/18/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011442 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $56,213.23 | 06/10/2025 | Non-covered Recipient Entity NRG WELLNESS CENTER | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190307101 |
| Principal investigator 1 | ModernaTX, Inc. | $39,015.68 | 05/28/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002521 |
| Principal investigator 1 | ModernaTX, Inc. | $22,249.76 | 05/28/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011434 |
| Principal investigator 1 | ModernaTX, Inc. | $22,683.90 | 05/28/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011454 |
| Principal investigator 1 | ModernaTX, Inc. | $682.50 | 05/07/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011440 |
| Principal investigator 1 | ModernaTX, Inc. | $25,964.64 | 04/28/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002511 |
| Principal investigator 1 | ModernaTX, Inc. | $42,119.20 | 04/28/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002519 |
| Principal investigator 1 | ModernaTX, Inc. | $18,147.12 | 04/28/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011432 |
| Principal investigator 1 | ModernaTX, Inc. | $4,641.00 | 04/02/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011446 |
| Principal investigator 1 | ModernaTX, Inc. | $3,000.00 | 04/01/2025 | Non-covered Recipient Entity JAVARA INC | Study of mRNA-1010 Seasonal Influenza Vaccine in Adults | No dispute reported | 06/30/2026 | 1252972773 |
| Principal investigator 1 | ModernaTX, Inc. | $18,147.12 | 03/24/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002507 |
| Principal investigator 1 | ModernaTX, Inc. | $23,474.88 | 03/24/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002517 |
| Principal investigator 1 | ModernaTX, Inc. | $10,197.28 | 03/24/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011452 |
| Principal investigator 1 | ModernaTX, Inc. | $1,012.08 | 03/24/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011462 |
| Principal investigator 1 | PFIZER INC. | $16,400.00 | 03/01/2025 | Non-covered Recipient Entity Javara Inc | AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228794434 |
| Principal investigator 1 | ModernaTX, Inc. | $1,012.08 | 02/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002503 |
| Principal investigator 1 | ModernaTX, Inc. | $9,073.56 | 02/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002505 |
| Principal investigator 1 | ModernaTX, Inc. | $33,252.00 | 02/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002513 |
| Principal investigator 1 | ModernaTX, Inc. | $26,359.84 | 02/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011444 |
| Principal investigator 1 | ModernaTX, Inc. | $21,849.75 | 02/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011456 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $5,560.00 | 02/04/2025 | Non-covered Recipient Entity JAVARA, INC | A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi | No dispute reported | 06/30/2026 | 1190310701 |
| Principal investigator 1 | ModernaTX, Inc. | $3,500.00 | 01/30/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011436 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $21,075.00 | 01/30/2025 | Non-covered Recipient Entity JAVARA, INC | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190310669 |
| Principal investigator 1 | ModernaTX, Inc. | $11,769.12 | 01/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252998183 |
| Principal investigator 1 | ModernaTX, Inc. | $23,244.31 | 01/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252998185 |
| Principal investigator 1 | ModernaTX, Inc. | $9,036.90 | 01/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252998187 |
| Principal investigator 1 | ModernaTX, Inc. | $1,173.15 | 01/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252998189 |
| Principal investigator 1 | ModernaTX, Inc. | $8,133.84 | 01/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252998191 |
| Principal investigator 1 | ModernaTX, Inc. | $6,659.31 | 01/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ?65 Years of Age | No dispute reported | 06/30/2026 | 1252998193 |
| Principal investigator 1 | ModernaTX, Inc. | $11,132.88 | 01/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253002509 |
| Principal investigator 1 | ModernaTX, Inc. | $21,724.64 | 01/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011428 |
| Principal investigator 1 | ModernaTX, Inc. | $8,106.54 | 01/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011430 |
| Principal investigator 1 | ModernaTX, Inc. | $16,634.86 | 01/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011438 |
| Principal investigator 1 | ModernaTX, Inc. | $16,637.92 | 01/27/2025 | Non-covered Recipient Entity JAVARA INC | A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age | No dispute reported | 06/30/2026 | 1253011450 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $24,187.64 | 01/27/2025 | Non-covered Recipient Entity NRG WELLNESS CENTER | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190307103 |
| Principal investigator 1 | PFIZER INC. | $663.65 | 01/25/2025 | Non-covered Recipient Entity Javara Inc | AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS | No dispute reported | 06/30/2026 | 1228800967 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $19,348.00 | 01/15/2025 | Non-covered Recipient Entity JAVARA, INC | a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older | No dispute reported | 06/30/2026 | 1185550938 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19,415.50 | 01/07/2025 | Non-covered Recipient Entity JAVARA, INC | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190310691 |